ATC Group: M09AX11 Palovarotene

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of M09AX11 in the ATC hierarchy

Level Code Title
1 M Musculo-skeletal system
2 M09 Other drugs for disorders of the musculo-skeletal system
3 M09A Other drugs for disorders of the musculo-skeletal system
4 M09AX Other drugs for disorders of the musculo-skeletal system
5 M09AX11

Active ingredients in M09AX11

Active Ingredient Description
Palovarotene

In patients with fibrodysplasia ossificans progressiva (FOP), abnormal bone formation, including heterotrophic ossification (HO), is driven by a gain-of-function mutation in the bone morphogenetic protein (BMP) type I receptor ALK2 (ACVR1). Palovarotene is an orally bioavailable retinoic acid receptor agonist, with particular selectivity at the gamma subtype of RAR. Through binding to RARγ, palovarotene decreases the BMP/ALK2 downstream signaling pathway by inhibiting the phosphorylation of SMAD1/5/8, which reduces ALK2/SMAD-dependent chondrogenesis and osteocyte differentiation resulting in reduced endochondral bone formation.

Related product monographs

Title Information Source Document Type  
SOHONOS Capsule MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.